Syndax Pharmaceuticals
SNDX
99 hedge funds and large institutions have $493M invested in Syndax Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 28 increasing their positions, 36 reducing their positions, and 14 closing their positions.
14% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 14
2% more funds holding
Funds holding: 97 → 99 (+2)
2% more capital invested
Capital invested by funds: $484M → $493M (+$9.52M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
10% less call options, than puts
Call options by funds: $1.12M | Put options by funds: $1.24M
1.63% less ownership
Funds ownership: 90.44% → 88.81% (-1.6%)
22% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$20.4M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$9.91M |
| 3 |
State Street
Boston,
Massachusetts
|
+$9.84M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$4.98M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$4.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$7.3M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.5M |
| 3 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$4.96M |
| 4 |
BlackRock
New York
|
-$4.05M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$3.92M |
SNDX Hedge Fund Activity: Q3 2020 in Review
99 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q3 2020, worth a combined $493M — up 2% from $484M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new SNDX positions and 14 closed out — a net gain of 2 holders — while 28 added to existing stakes and 36 trimmed.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $20.4M. The largest seller was Citadel Advisors, cutting an estimated $7.3M.
- 99 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q3 2020, up from 97 in Q2 2020.
- Funds reported $493M of Syndax Pharmaceuticals stock for Q3 2020, up 2% quarter-over-quarter.
- 16 funds opened new Syndax Pharmaceuticals positions in Q3 2020 and 14 closed out, a net change of +2 holders.
- The largest Syndax Pharmaceuticals buyer in Q3 2020 was Nantahala Capital Management, an estimated $20.4M added.
- The largest Syndax Pharmaceuticals seller in Q3 2020 was Citadel Advisors, an estimated $7.3M sold.
Based on aggregated 13F filings for Q3 2020.